Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Norethindrone acetate Clear all
Completed Phase 3 Interventional Results available

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274
View directory record Official record
Conditions
Endometriosis
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
60
States / cities
Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Ovulation Incidence in Oral Contraceptive Users

NCT03106454
View directory record Official record
Conditions
Contraception, Ovulation
Interventions
Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 22, 2026, 11:21 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age

NCT03905941
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral combined hormonal contraceptives
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03412890
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
104
States / cities
Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Treatment of Endometriosis-Associated Pelvic Pain

NCT00229996
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Oral Contraceptive, Depot-Leuprolide/Norethindrone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 52 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

NCT04756037
View directory record Official record
Conditions
Contraception
Interventions
Relugolix Combination Therapy
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
109
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Not applicable Interventional Results available

Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study

NCT00600106
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
1/10 NA/EE, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 22, 2026, 11:21 AM EDT
Terminated No phase listed Observational

A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

NCT05026502
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 22, 2026, 11:21 AM EDT
Recruiting Phase 3 Interventional

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

NCT05862272
View directory record Official record
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 22, 2026, 11:21 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

NCT02210702
View directory record Official record
Conditions
Postpartum Depressive Mood, Postpartum Sexual Function
Interventions
Ethinyl Estradiol 35mcg/Norethindrone 1mg, Ethinyl Estradiol 20mcg/Norethindrone 1mg
Drug
Lead sponsor
The Jones Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 22, 2026, 11:21 AM EDT
Recruiting Early Phase 1 Interventional

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

NCT07568509
View directory record Official record
Conditions
Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
Interventions
Norethindrone Acetate-Ethinyl Estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study

NCT00522873
View directory record Official record
Conditions
Postmenopause
Interventions
0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 22, 2026, 11:21 AM EDT
Completed No phase listed Observational

Norethindrone Impact on Receptiva Outcomes

NCT07134920
View directory record Official record
Conditions
Infertility (IVF Patients), Infertility Female
Interventions
Not listed
Lead sponsor
Inception Fertility Research Institute, LLC
Industry
Eligibility
Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

NCT01391052
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
Interventions
Norethindrone acetate pretreatment, No pretreatment
Drug · Other
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

NCT01344369
View directory record Official record
Conditions
Healthy
Interventions
Norethindrone/Ethinyl Estradiol, FEMCON® Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

NCT02705963
View directory record Official record
Conditions
Solid Tumors
Interventions
Trametinib, Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 22, 2026, 11:21 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

NCT07766369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

NCT00006133
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older · Female only
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262740
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Progestin-Only Pill Use and Breastfeeding Study

NCT04965116
View directory record Official record
Conditions
Contraception, Breastfeeding
Interventions
Progestin Only Contraceptive Pills
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 22, 2026, 11:21 AM EDT
Recruiting Phase 3 Interventional

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

NCT07100782
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Relugolix CT
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 22, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Safety and Efficacy of an Oral Contraceptive

NCT00932321
View directory record Official record
Conditions
Prevention of Pregnancy
Interventions
Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 22, 2026, 11:21 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

NCT05538689
View directory record Official record
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 22, 2026, 11:21 AM EDT